Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer and can be defined as any type of epithelial lung cancer other than SCLC.&nbsp;
PD-L1 (also known as CD274) is considered an immune checkpoint is facilitating anti-tumour suppression of the immune pathway.
&nbsp;
Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Epidemiological Segmentation&nbsp;
The Epidemiological Segmentation of Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) in 7MM from 2017 to 2030 is segmented as:-&nbsp;
<ul>
<li>Total Incident Cases of NSCLC</li>
<li>Total Incident Cases of NSCLC Patients by Histology</li>
<li>Total Diagnosed Cases of NSCLC Patients by Stages</li>
<li>Total NSCLC cases of patients by PD-L1</li>
<li>Total Treated cases of NSCLC patients by Line of Therapies</li>
</ul>
&nbsp;
Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Epidemiology&nbsp;
<ul>
<li>Total cases of Programmed death-ligand 1 (PD-L1) mutated NSCLC in 7MM in 2017 were&nbsp;242,014&nbsp;Programmed death-ligand 1 (PD-L1) NSCLC cases in the United States in 2017 were&nbsp;89,597&nbsp;</li>
</ul>
&nbsp;
<a style="color: #0066cc; background-color: transparent;" href="https://www.delveinsight.com/report-store/programmed-death-ligand-1-pd-l1-non-small-cell-lung-cancer-nsclc-market" target="_blank" rel="noopener noreferrer">Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Market</a>
The market size of Programmed death-ligand 1 (PD-L1) mutated NSCLC in 7MM in 2017 was&nbsp;USD 6,536 million.&nbsp;
&nbsp;
Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Market Drivers
<ul>
<li>Increasing Use of Biomarker Testing&nbsp;</li>
<li>Increase in the Mutation Specific Trials Activity</li>
<li>Increasing Incidence of Programmed death-ligand 1 (PD-L1) mutated NSCLC</li>
</ul>
&nbsp;
Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Market Barriers
<ul>
<li>Cost-Effectiveness of Therapies</li>
<li>Cost of Therapies</li>
<li>Burden of Disease</li>
</ul>
&nbsp;
Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Emerging Drugs
The Emerging drugs of the Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) market are&nbsp;
<ul>
<li>Canakinumab (ACZ885)</li>
<li>Avelumab (Bavencio)</li>
<li>Libtayo (Cemiplimab)</li>
<li>M7824 (Bintrafusp alfa)</li>
</ul>
And many others.&nbsp;
&nbsp;
Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Key Players
The key players in the Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) market are
<ul>
<li>Novartis Pharmaceutical</li>
<li>Merck KGaA&nbsp;</li>
<li>Pfizer</li>
<li>Regeneron Pharmaceuticals</li>
<li>GlaxoSmithKline</li>
</ul>
And many others.&nbsp;

PD-L1 Non-Small Cell Lung Cancer (PD-L1+ NSCLC) Market

PD-L1Non-Small Cell Lung Cancer (PD-L1+ NSCLC) Market

PD-L1 Non-Small Cell Lung Cancer (PD-L1+ NSCLC) Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.